RSV Drug Pipeline: High-Risk Adults — PatSnap Eureka
RSV Drug Pipeline: Antiviral & Monoclonal Approaches for High-Risk Adults
Respiratory syncytial virus carries mortality rates of 30–100% in transplant recipients. Explore the patent and literature landscape for antivirals, monoclonal antibodies, RNAi, and mRNA strategies targeting immunocompromised and high-risk adult populations.
RSV Targets Driving Drug Development in Vulnerable Populations
RSV drug development is concentrated on two primary surface glycoproteins. The RSV F protein (fusion protein) is the most frequently cited target across retrieved records. It mediates viral membrane fusion and exists in a metastable prefusion (pre-F) conformation and a stable postfusion (post-F) conformation. The pre-F conformation harbors more potent neutralization epitopes, particularly antigenic sites II/A, Ø, and V — a finding explicitly highlighted in a 2026 Xiamen University patent filing.
The RSV G protein (attachment glycoprotein) is a secondary but emerging target. While highly variable between RSV subtypes A and B, a conserved central domain at residues 153–184 in the A2 strain represents a viable antibody epitope. U.S. Government (DHHS) 2025 patent filings describe G-protein-targeting mAbs with IC50 values as low as 0.4 ng/ml, derived from B-cell receptor sequencing of human RSV challenge study participants — exceeding the potency of previously disclosed RSV neutralizing antibodies.
The RSV RdRp (L protein polymerase complex) is targeted by nucleoside analog antivirals. According to WHO and the literature, ribavirin remains the historically sole approved antiviral for RSV treatment, though its efficacy is consistently noted as limited or unproven for shortening hospitalization. The F protein sequence is approximately 89–91% conserved between RSV-A and RSV-B subtypes, making it a viable pan-subtype target.
Clinically relevant high-risk populations identified across retrieved records include: bone marrow transplant recipients, patients with COPD, congestive heart failure, chronic lung disease, nursing home residents, and immunocompromised adults. Palivizumab-resistant RSV strains exist in clinical isolates, with resistance mapping to antigenic site II/A mutations — a documented problem motivating next-generation antibody strategies.
Eight Modality Classes in the RSV Drug Pipeline
From approved monoclonal antibodies to emerging mRNA and RNAi platforms, the RSV pipeline spans a wide range of therapeutic strategies — with particular relevance for immunocompromised patients where active vaccination responses are blunted.
Anti-RSV F Protein Monoclonal Antibodies
The most densely represented modality in the dataset. MedImmune/AstraZeneca holds the largest portfolio, covering palivizumab dosing methods, motavizumab, and nirsevimab (MEDI8897) across 12+ jurisdictions. Nirsevimab targets pre-F site Ø with extended half-life; Phase IIb data show 70.1% reduction in outpatient visits and 78.4% reduction in hospitalizations. Regeneron's fully human anti-F antibodies explicitly target immunocompromised adults including bone marrow transplant patients.
Phase III / ApprovedAnti-RSV G Protein Monoclonal Antibodies
Recent U.S. Government (DHHS) 2025 WO filings disclose antibodies 68C7, 73C1, 77D2, 40D8, and others derived from B-cell receptor sequencing of human RSV challenge study participants, with IC50 values as low as 0.4 ng/ml. Crucell Holland B.V. (J&J) covers antibodies targeting the conserved central domain of G protein, neutralizing both RSV A and B subtypes. The approach addresses the variability limitation of G protein by focusing on the conserved central domain.
Preclinical / Early Dev.Recombinant Polyclonal Antibodies
Symphogen A/S pioneered recombinant polyclonal antibody approaches targeting multiple epitopes on both RSV F and G proteins simultaneously, with picomolar-affinity individual mAb components. The rationale — that single-specificity antibodies may be insufficient given RSV escape mutant emergence — is explicitly stated across multiple Symphogen filings. This approach is designed to overcome palivizumab-resistant escape mutants, a documented clinical problem.
PreclinicalSmall Molecule Fusion Inhibitors
Multiple patent families cover small molecule RSV entry inhibitors targeting the F protein fusion mechanism. Key scaffolds include imidazo[4,5-c]pyridinone-based compounds (Janssen), polycyclic agents (Biota), benzo[b]thieno[2,3-d]azepine compounds (Roche, active ES jurisdiction), and replication inhibitors (Janssen Pharmaceutica N.V.). MDT-637, a fusion inhibitor, has been evaluated against clinical RSV isolates in HEp-2 cells, with IC50 comparisons against ribavirin.
Preclinical / Early ClinicalNucleoside Analogs (RdRp Inhibitors)
Ribavirin is referenced across multiple retrieved records as the historically sole approved antiviral for RSV treatment, with consistent notes that its efficacy is limited or unproven for shortening hospitalization or reducing supportive care requirements. Merck's 2009 patent covers next-generation nucleoside scaffolds (C2–4 alkenyl/alkynyl series) as improved RdRp inhibitors. The literature consistently identifies this as an area of unmet therapeutic need in high-risk adult populations.
Ribavirin Approved (limited)RNAi / siRNA via Inhaled Delivery
Alnylam Pharmaceuticals' 2009 patent covers siRNA agents administered as nasal spray or inhaled respirable particles/droplets, with in vitro inhibition of both RSV-A and RSV-B subtypes in plaque assays and in vivo reduction of viral titers in mouse models using a dose-dependent response. The topical respiratory delivery strategy could achieve high local concentrations in the respiratory mucosa independent of systemic immune status — a potential advantage in immunocompromised hosts who cannot rely on systemic immune responses.
Preclinical (Mouse Models)Nanobody (Single-Domain Antibody) Constructs
Ablynx's 2012 patent describes mono-, bi-, and trivalent VHH (nanobody) constructs targeting hRSV F protein, including bivalent humanized NC41 nanobody formats. Enhanced stability and reduced immunogenicity relative to conventional antibodies are claimed. The compact single-domain format offers potential advantages for respiratory delivery and manufacturing compared to full-length IgG antibodies.
Preclinical / Early Dev.mRNA-Encoded Antibodies & Vaccines
Two emerging modalities appear in recent filings: mRNA encoding RSV F protein for active immunization (Pfizer 2025 patent, covering RNA-LNP formulations) and RNA encoding therapeutic antibodies (CureVac AG 2020 patent). For immunocompromised patients who may not mount sufficient responses to active vaccines, mRNA-delivered antibody approaches may retain distinct clinical value. IP in this intersection remains less crowded than the prophylactic pediatric space.
Preclinical / Early ClinicalRSV Pipeline Patent Signals at a Glance
Key quantitative signals from patent and literature analysis across the RSV drug pipeline, derived exclusively from retrieved records via PatSnap Eureka.
RSV Patent Density by Therapeutic Modality
Anti-F mAbs dominate the patent landscape; emerging modalities like anti-G mAbs and mRNA platforms represent less-crowded IP spaces.
Nirsevimab Phase IIb Efficacy Signals vs. Control
Phase IIb data referenced in MedImmune Limited filings show substantial reductions in RSV-related healthcare utilisation vs. placebo control.
Top Patent Assignees in RSV Drug Pipeline
MedImmune/AstraZeneca holds the dominant portfolio position; U.S. DHHS and Janssen are significant secondary filers across distinct modality spaces.
RSV Drug Targets: Patent Focus Distribution
F protein (fusion) dominates therapeutic targeting; G protein and RdRp represent emerging and underserved target categories in this dataset.
Next-Generation RSV Approaches: Combinations, Cross-Virus, and Immunomodulation
Retrieved records signal several combination and emerging strategies that may be particularly relevant for immunocompromised patients and those with palivizumab-resistant RSV strains.
Small Molecule + mAb Combinations (Janssen)
Janssen's combination product patents define pairings of Compound A (indole-imidazo[4,5-c]pyridinone fusion inhibitor) with a broad menu of RSV inhibitors including ribavirin, GS-5806 (presatovir), MDT-637, BTA-9881, BMS-433771, MEDI8897 (nirsevimab), and palivizumab. This is the most comprehensive combination IP strategy in this dataset — analogous to combination approaches in HIV and HCV — offering synergistic antiviral activity and a higher barrier to resistance.
Anti-RSV + Anti-TNFα Dual Antibody Approaches
A patent from Pollack/Abbott Biotechnology Ltd. (2006) and related WO, EP, TW family members claim anti-TNFα antibody (adalimumab) combined with anti-RSV antibody for prevention of RSV-associated disorders, targeting both viral replication and the pathological inflammatory response. This immunomodulatory approach may be particularly relevant to patients with inflammatory comorbidities (COPD, CHF) and immunocompromised patients where dysregulated inflammatory responses complicate RSV disease.
Key Patent Assignees & Strategic IP Signals
The RSV patent landscape is concentrated, with MedImmune/AstraZeneca holding the most fortified position. Understanding the assignee map is critical for freedom-to-operate analysis and white space identification.
| Assignee | Primary Modality Focus | Jurisdictions | Key IP Signal | Stage |
|---|---|---|---|---|
| MedImmune Ltd. / AstraZeneca | Anti-F mAbs: palivizumab, motavizumab, nirsevimab (MEDI8897) | AU, CA, EP, JP, IL, IN, SG, TW, BR, US, WO, CN | 12+ patent families; active pending filings 2021–2025; dosing regimen + fixed-dose composition claims | Approved / Active |
| U.S. Government (DHHS) | Anti-G mAbs (68C7, 73C1, 77D2, 40D8); anti-F mAbs; attenuated chimeric RSV vaccines | WO (2025 filings) | G-protein mAbs with IC50 as low as 0.4 ng/ml from human challenge study B-cell sequencing | Preclinical |
| Janssen Sciences Ireland UC / Janssen Pharmaceutica N.V. | Small molecule fusion/replication inhibitors; combination products | US, WO, EP | Combination IP pairing Compound A with 14+ named RSV inhibitors including nirsevimab and palivizumab | Early Clinical |
| Regeneron Pharmaceuticals | Fully human anti-RSV F antibodies | US (2019 filings) | Explicit recognition of immunocompromised adults (bone marrow transplant, COPD, CHF) as target populations | Preclinical / Dev. |
| Symphogen A/S | Recombinant polyclonal antibodies (F + G dual targeting) | WO, EP | Picomolar-affinity components; designed to overcome palivizumab-resistant escape mutants | Preclinical |
| Pfizer Inc. | mRNA-LNP encoding RSV-F for active immunization | WO (2025) | RNA-LNP formulations for RSV-F active immunization; convergence with pre-F stabilized antigen strategies | Early Clinical |
Identify Freedom-to-Operate Risks in RSV Drug Development
PatSnap Eureka maps claim scope, jurisdiction coverage, and expiry timelines across the full RSV patent estate. Used by 18,000+ innovators globally.
From Bench to Bedside: Key Clinical Data in the RSV Pipeline
Nirsevimab Phase III: Clinical trial data from 921 nirsevimab-treated subjects and 466 placebo subjects report anti-drug antibody (ADA) rates of 4.3% vs. 2.8% in placebo, with no pharmacokinetic or safety impact. Phase IIb data show 70.1% reduction in outpatient visits and 78.4% reduction in hospitalizations vs. control — the strongest efficacy signals in this dataset.
Palivizumab treatment trial (Malley et al.): Phase I/II clinical data on IV palivizumab (15 mg/kg single dose) in RSV-hospitalized children found statistically significant reduction in lung viral titers but no improvement in hospitalization duration, oxygen therapy days, or LRI scores — a key limitation establishing the case for next-generation therapeutic mAbs.
MDT-637 translational analysis: A 2017 paper from Children's Foundation Research Institute at Le Bonheur Children's Hospital provides IC50 data for MDT-637 and ribavirin against RSV clinical isolates in HEp-2 cells, benchmarked against achievable human respiratory tract concentrations — representing an IND-enabling type translational analysis for this fusion inhibitor. According to NIH, translational pharmacokinetic benchmarking is a critical step in antiviral IND preparation.
Health economics (LSHTM, 2019): A Bayesian-calibrated RSV transmission model integrated with economic analysis by the London School of Hygiene and Tropical Medicine determines cost-effective purchase price thresholds for long-acting mAbs and new vaccines, finding that 2–14% of infants are born with maternal RSV protection. This represents a payer decision-making signal for next-generation prophylactics.
Critical gap: No retrieved record explicitly contains data on RSV therapeutic trials in immunocompromised adults as a primary endpoint population — representing a documented white space in both the clinical and IP landscape. The patent analytics signal is clear: this population is identified as high-unmet-need but lacks a discrete, dedicated patent cluster.
RSV Drug Pipeline in High-Risk Adults — Key Questions Answered
Retrieved results consistently identify two primary surface glycoproteins as dominant therapeutic targets: the RSV F protein (fusion protein), which is the most frequently cited target, and the RSV G protein (attachment glycoprotein), an emerging secondary target. The F protein's prefusion conformation (pre-F) harbors more potent neutralization epitopes, particularly antigenic sites II/A, Ø, and V. The RSV RdRp (L protein polymerase complex) is also targeted by nucleoside analog antivirals such as ribavirin.
Clinically relevant patient populations at elevated RSV risk include bone marrow transplant recipients, patients with COPD, congestive heart failure, chronic lung disease, nursing home residents, and immunocompromised adults. Mortality in transplant recipients is cited as 30–100% when RSV infection occurs in the early post-transplant window.
Nirsevimab is a next-generation, extended-half-life anti-RSV F monoclonal antibody targeting pre-F site Ø. Phase IIb data referenced in MedImmune Limited filings show a 70.1% reduction in outpatient visits and 78.4% reduction in hospitalization vs. control. Clinical trial data from 921 nirsevimab-treated subjects report anti-drug antibody (ADA) rates of 4.3% vs. 2.8% in placebo, with no effect on pharmacokinetics or safety.
Janssen's combination product patents define combinations of Compound A (indole-imidazo[4,5-c]pyridinone fusion inhibitor) with a broad menu of RSV inhibiting candidates including ribavirin, GS-5806 (presatovir), MDT-637, BTA-9881, BMS-433771, MEDI8897 (nirsevimab), and palivizumab. Anti-TNFα antibody (adalimumab) combined with anti-RSV antibodies is also claimed for RSV-associated disorders, targeting both viral replication and pathological inflammatory response.
Palivizumab-resistant RSV strains exist in clinical isolates, with resistance mapping to antigenic site II/A mutations. This motivates antibodies targeting alternative epitopes or multiple epitopes simultaneously. Aridis Pharmaceuticals explicitly addresses palivizumab-resistant RSV strains, disclosing F-protein antibodies that neutralize at least one palivizumab-resistant strain. Symphogen's recombinant polyclonal antibody approach was also designed to overcome palivizumab-resistant escape mutants.
MedImmune LLC / MedImmune Limited (AstraZeneca) is the single most dominant assignee in this dataset, with over a dozen patent families covering anti-RSV antibody dosing methods and nirsevimab-specific dosage regimens across AU, CA, EP, JP, IL, IN, SG, TW, BR, US, WO, and CN jurisdictions. Other key actors include U.S. Government (DHHS), Janssen Sciences Ireland UC, Regeneron Pharmaceuticals, Symphogen A/S, Crucell Holland B.V., Alnylam Pharmaceuticals, GlaxoSmithKline Biologicals, Icosavax, Pfizer, and CureVac AG.
Still have questions about RSV patent strategy or drug development? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About RSV PatentsAccelerate RSV Drug Pipeline Intelligence for High-Risk Populations
Join 18,000+ innovators already using PatSnap Eureka to analyse drug pipelines, map IP white spaces, and identify therapeutic opportunities in immunocompromised patient populations.
References
- Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase — Merck & Co., Inc., 2009 [Patent]
- Combination products for the treatment of RSV — Janssen Sciences Ireland Unlimited Company, 2021 [Patent]
- Dosage regimens for and compositions including Anti-RSV antibodies — MedImmune Limited, 2021 [Patent]
- Prevention of RSV lower respiratory tract infection with nirsevimab — MedImmune Limited, 2024 [Patent]
- Neutralizing and protective monoclonal antibodies against RSV — U.S. Government (DHHS), 2025 [Patent]
- RSV G and F antibodies with high RSV-neutralizing potency — U.S. Government (DHHS), 2025 [Patent]
- Human antibodies to respiratory syncytial virus F protein and methods of use thereof — Regeneron Pharmaceuticals, Inc., 2019 [Patent]
- Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections — Symphogen A/S, 2011 [Patent]
- Methods and compositions for prevention or treatment of RSV infection — Alnylam Pharmaceuticals Inc., 2009 [Patent]
- Monovalent, bivalent, and trivalent anti-human RSV nanobody constructs — Ablynx NV, 2012 [Patent]
- Treatment of RSV infection — Pollack/Abbott Biotechnology Ltd., 2006 [Patent]
- Broadly neutralizing antibodies against RSV and MPV paramyxoviruses — Humabs BioMed SA, 2025 [Patent]
- RNA molecules encoding RSV-F and vaccines containing such RNA molecules — Pfizer Inc., 2025 [Patent]
- Methods for preventing CoV and/or RSV infection — Starpharma Holdings Limited, 2023 [Patent]
- The antiviral effects of RSV fusion inhibitor MDT-637 on clinical isolates — Children's Foundation Research Institute at Le Bonheur Children's Hospital, 2017 [Paper]
- Cost-effectiveness of the next generation of RSV intervention strategies — London School of Hygiene and Tropical Medicine, 2019 [Paper]
- World Health Organization (WHO) — RSV disease burden and antiviral guidance
- National Institutes of Health (NIH) — Antiviral IND preparation and translational pharmacokinetics
- London School of Hygiene and Tropical Medicine — RSV health economics modelling
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.